key: cord-0940223-vm6agssg authors: de Castillo, Lennie Lynn C.; Diestro, Jose Danilo B.; Ignacio, Katrina Hannah D.; Separa, Karl Josef NiƱo J.; Pasco, Paul Matthew D.; Franks, Maria Carissa P. title: Concurrent Acute Ischemic Stroke and Non-Aneurysmal Subarachnoid Hemorrhage in COVID-19 date: 2020-11-05 journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques DOI: 10.1017/cjn.2020.242 sha: d37996935fc5145ab1e8c6a24a3d3bafd59c57eb doc_id: 940223 cord_uid: vm6agssg nan Cerebrovascular disease has been described as a potential sequela of the novel coronavirus disease of 2019 (COVID-19) with one study reporting its occurrence in 106 patients. In this rapid review, 83% of the patients had ischemic strokes, while 17% were hemorrhagic. 1 Most of the hemorrhagic strokes were either intracerebral hemorrhage or aneurysmal subarachnoid hemorrhage. The mortality of COVID-19 patients with cerebrovascular events can be as high as 38%. 2 As of this writing, there has been no reported case of a COVID-19 patient with concurrent acute ischemic and hemorrhagic strokes. We report a case of a 64-year-old male, hypertensive and smoker, who came to our emergency department for sudden onset right-sided weakness, numbness, and dysarthria. There was no history of trauma or respiratory symptoms prior to admission. He had no prior use of antithrombotics. He works as a utility worker in the designated COVID-19 area of the hospital. On examination, he had a blood pressure of 150/90 with a normal heart rate and regular rhythm right superior quadrantanopia, right hypesthesia, and right hemiparesis. His National Institute of Health Stroke Scale (NIHSS) score was 7. A 12-lead electrocardiogram showed sinus rhythm. A plain cranial CT scan revealed an acute infarct on the left thalamus and left temporo-occipital lobe, as well as a small subarachnoid hemorrhage on the left parietal sulcus ( Figure 1 ). The cranial CT angiogram (CTA) did not show any acute large vessel occlusions, aneurysms, or venous thrombosis. His severe acute respiratory syndrome coronavirus-2 reverse transcriptase polymerase chain reaction (SARS-CoV 2 RT-PCR) was positive. Chest X-ray showed pneumonia. He had a normal complete blood count, prothrombin time, international normalized ratio, partial thromboplastin time, ferritin, erythrocyte sedimentation rate, and high sensitivity C-reactive protein. D-Dimer and lactate dehydrogenase were slightly elevated at 0.66 mcg/ml and 209 U/l, respectively. Institutional limitations precluded an urgent catheter angiogram. He was started on Aspirin 160 mg once a day for secondary stroke prevention after an aneurysm was ruled out and was discharged with a modified Rankin scale score of 4 after 14 days. Anticoagulation was not given due to the concurrent subarachnoid hemorrhage. Recent studies reported that COVID-19 increases the risk of cerebrovascular diseases. The exact mechanism by which the virus can involve the nervous system is still unclear. However, the proposed pathophysiology suggests that it may be a multifactorial process. Possible routes of SARS-CoV-2 in the cerebrovascular system include the olfactory epithelium and the respiratory tract with subsequent viremia. 1 The virus can bind to the ACE-2 receptors of the cerebrovascular endothelium and causes endothelial damage and induces cytokine storm, which can then lead to vasculitis and subsequent stroke. 3 Endothelial dysfunction and the consequent hyperinflammatory reaction may also increase the risk of plaque rupture and thrombosis. 4 A hypercoagulable state is also another mechanism by which the virus can cause stroke, as evidenced by the increase in Ddimer seen in our patient. 5, 6 These mechanisms may explain why our patient had ischemic stroke. The disease is also associated with a downregulation of the ACE-2 receptors, elevated angiotensin II levels, and aforementioned endothelial damage, which can cause an increase in blood pressure and subsequently increase the risk for hemorrhagic stroke. 4 The presence of other well-known risk factors for stroke, such as hypertension and smoking in our patient may have placed him at a greater risk for acquiring COVID-19 and developing cerebrovascular disease. Non-aneurysmal SAH has previously been reported in a COVID-19 patient. 7 However, the co-occurrence of acute ischemic stroke and non-aneurysmal SAH has not been documented previously. The location of the patient's subarachnoid hemorrhage is far from the infarcted tissue, making the diagnosis of a hemorrhagic infarct or a delayed cerebral ischemia from vasospasm unlikely. This suggests the possibility that the proposed mechanisms in COVID-19-related stroke can happen simultaneously, predisposing the patients to both types of stroke. Whether this finding is associated with COVID-19 or just coincidental is yet to be elucidated in future researches. Informed consent was obtained from the patient prior to submission for publication. Neurological associations of COVID-19 Acute ischemic and hemorrhagic stroke in COVID-19 : mounting evidence case presentation SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven article SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Influence of COVID-19 on cerebrovascular disease and its possible mechanism Neurological manifestations in COVID-19 infection: a systematic review and meta-analysis Extrapulmonary manifestations of COVID-19 Novel coronavirus disease 2019 and subarachnoid hemorrhage: a case report